Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zydus Cadila has received an approval from the Drug Controller General of India (DCGI) to market the H1N1 (swine flu) vaccine.
Subscribe to our email newsletter
Zydus Cadila has claimed that with this, it will become the first Indian pharma company to launch its vaccine which will be marketed under the brand name VaxiFlu-S.
VaxiFlu-S is expected to be marketed by Vaxxicare – a division of the group focussing on preventives. A dedicated taskforce has also been set up to market the vaccine. The egg based, inactivated vaccine based on conventional technology has been developed by the group’s researchers at its Vaccine Technology Centre (VTC) in Ahmedabad.
VTC further plans to develop a wide spectrum of vaccines against bacterial, viral and protozoal infections. With the development and launch of VaxiFlu–S, Zydus now has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines. The group also markets the anti-rabies vaccine and the typhoid vaccine.
Pankaj Patel, chairman and managing director of Zydus Cadila, said: “With the vaccine in the market soon, we would be better prepared with an affordable therapy and prevent further loss of lives to this infectious disease. The launch of VaxiFlu-S gives thrust to our objective of emerging as a strong player in the area of preventives.”